MeiraGTx Announces Oral Presentation at ObesityWeek 2026
Globe Newswire•16/11/2026•07:00 ET
2
Key Highlights
- ➤AAV-BDNF restored metabolic homeostasis for over 14 months in diet-induced obese mice
- ➤BDNF(+/-) mice showed significant weight stabilization and normalized glucose tolerance
- ➤Ultra-low unilateral doses produced therapeutic rescue with favorable systemic safety results
- ➤Treatment reduced aggressive and perseverative chasing without impairing pro-social interactions
- ➤MeiraGTx presented preclinical obesity findings at ObesityWeek 2026
LONDON and NEW YORK, Nov. 16, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced the Company will have an oral presentation at ObesityWeek, in Washington, DC, at 8:30 am ET at the Gaylord National Resort & Convention Center. Hosted annually by The Obesity Society (TOS), ObesityWeek is a premier international scientific conference focused on the multi-disciplinary science, treatment, and prevention of obesity.
The presentation will be available on the Posters and Publications page of the Company’s website.
Get started
Create a free account to read the full story.
